| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 548311100 | Additional hetero ring attached directly or indirectly to the diazole ring by nonionic bonding (e.g., 1,3-dioxolan-2-yl methyl-imidazole, etc.) | 31 |
| 20110257409 | Ionic Liquid Epoxy Resin Monomers - Ionic liquid epoxide monomers capable of reacting with cross-linking agents to form polymers with high tensile and adhesive strengths. Ionic liquid epoxide monomers comprising at least one bis(glycidyl) N-substituted nitrogen heterocyclic cation are made from nitrogen heterocycles corresponding to the bis(glycidyl) N-substituted nitrogen heterocyclic cations by a method involving a non-nucleophilic anion, an alkali metal cation, epichlorohydrin, and a strong base. | 10-20-2011 |
| 20120130082 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same - The present invention relates to a 1-substituted-4-nitroimidazole compound represented by the general formula (1) or a salt thereof, | 05-24-2012 |
| 548311400 | The additional hetero ring is a cyclo in a polycyclo ring system [e.g., 2-(1-isothiochromanyl)-2-imidazoline hydrochloride, etc.] | 9 |
| 20090005573 | Method for Manufacturing Imidazole Compounds and Salts and Pseudopolymorphs Thereof - The invention relates to a method for manufacturing sertaconazole mononitrate. The invention also relates tcserta-conazole mononitrate that is characterized by it: particle size and to sertaconazole mononitrate monohydrate. | 01-01-2009 |
| 20100113799 | Process for the Preparation of (R) - 5 - (2-Aminoethyl) -1- (6, 8-Difluorochroman-3-YL) -1,3-Dihydroimidazole-2-Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-06-2010 |
| 20100121073 | Process for the Preparation of (R)-5-(2-Aminoethyl)-1-(6,8-Difluorochroman-3-YL)-1,3-Dihydroimidazole-2-- Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-13-2010 |
| 20110166360 | Catalytic Process for Asymmetric Hydrogenation - A process for preparing the S or R enantiomer of a compound of formula A, | 07-07-2011 |
| 20140031561 | Crystalline Forms and Processes for Their Preparation - The present invention relates to crystalline Form A of 1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-5-[2-[(phenylmethyl)amino]ethyl]-2H-imidazole-2-thione and crystalline Form B of 1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-5-[2-[(phenylmethyl)amino]ethyl]-2H-imidazole-2-thione, processes for preparing the forms and their uses in medicine. The present invention also relates to the amorphous form of 1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-5-[2-[(phenylmethyl)amino]ethyl]-2H-imidazole-2-thione processes for preparing it and its uses in medicine. | 01-30-2014 |
| 20140221668 | Process - The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se. | 08-07-2014 |
| 548311700 | At least two ring hetero atoms in the polycyclo ring system | 1 |
| 20100179331 | FURANOSE DERIVATIVES - The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said derivatives in the manufacture of atorvastatin. | 07-15-2010 |
| 548312100 | The additional polycyclo ring system is a bicyclo ring system having nitrogen as the only ring hetero atom [e.g., 5-(indolyl-3-methylene)- hydantoin, etc.] | 2 |
| 20100217009 | Process for Preparing Chroman Derivatives - A process for preparing a compound of formula (22), comprising reducing a compound of formula (21), to produce a compound of formula (23), followed by the hydrogenolysis of the compound of formula 23 in a solvent comprising a C | 08-26-2010 |
| 20130338371 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING RING STRUCTURE THAT INCLUDES NITROGEN ATOM OR OXYGEN ATOM - The invention is a method for efficiently producing an aromatic compound by an intramolecular cyclization reaction, the aromatic compound having a ring structure that includes a nitrogen atom or oxygen atom. An aromatic compound composed of tert-butyl-2-(3-oxo-3-phenylpropyl)phenyl carbamate or another aniline derivative or the like, or an aromatic compound composed of 3-(1-hydroxynaphthalene-2-yl)propionic acid or another naphthol derivative or the like is made to react in a system to which an oxidizing agent and a quaternary ammonium salt represented by general formula (1) are fed. In the formula, X is an iodine atom; and R | 12-19-2013 |
| 548312400 | The additional hetero ring is a diazole ring (including hydrogenated) | 13 |
| 548312700 | Plural 1,3-diazoles | 13 |
| 20120232287 | DETERGENT DISPERSANT AND LUBRICATING OIL COMPOSITION - A detergent dispersant contains a nitrogen-containing compound represented by the following formula (1). A lubricating oil composition contains the detergent dispersant. | 09-13-2012 |
| 20130217889 | NOVEL PHASE TRANSFER CATALYSTS - Compounds of formula (I): wherein R | 08-22-2013 |
| 20130245280 | AMINE COMPOUND AND USE FOR SAME - Provided is an ester of 3-[(4-dipropylamino-butyl)(4-{[(1H-imidazole-2-ylmethyl)(1-methyl-1H-imidazole-2-ylmethyl)amino]methyl}benzyl)amino]propionic acid which is easily hydrolyzed in serum. The amine compound of the present invention is an ester compound represented by general formula (1). (In general formula (1), n is 1-4, and R | 09-19-2013 |
| 548313100 | Additional diverse hetero ring attached directly or indirectly to a diazole ring by nonionic bonding | 3 |
| 20080255368 | Tgf-ß Gene Expression Inhibitor - A TGF-β gene expression inhibitor containing a pyrrole-immidazole polyamide comprising an N-methylpyrrole unit (hereinafter also referred to as Py), an N-methylimidazole unit (hereinafter also referred to as Im) and a γ-aminobutyric acid unit which can be folded into an U-shaped conformation at the above-described γ-aminobutyric acid unit site in a minor groove of a double-stranded region (hereinafter referred to as the target region) containing a part or the whole of the following base sequence (SEQ ID NO: 2) corresponding to −450 to −310 of human transforming growth factor β1 (hereinafter also referred to as h TGF-β1) promoter and a strand complementary thereto and in which a Py/Im pair, an Im/Py pair and a PY/Py pair correspond respectively to a C-G base pair, a G-C base pair and an A-T base pair and a T-A base pair. | 10-16-2008 |
| 20090043107 | Process for Synthesizing Compounds Useful for Treating Hepatitis C - The present disclosure generally relates to a process for synthesizing methyl ((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3- methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to intermediates useful in this process. | 02-12-2009 |
| 20090171097 | AUTOMATED SOLID PHASE SYNTHESIS OF PYRROLE-IMIDAZOLE POLYAMIDE - A synthesis method for pyrrole-imidazole polyamide is automated at a higher level and can produce a product with a high yield in a more stable manner. In a solid phase synthesis method, the automated synthesis of a polyimide can be promoted by using HCTU as a condensation-activator, the yield of a product can be increased by charging a monomer in a solid form, and a pyrrole-imidazole polyamide having any sequence can be synthesis by combining the synthesis method with a manual synthesis with an acid chloride. | 07-02-2009 |
| 548313400 | The diazole rings are bonded directly to each other | 1 |
| 20120203008 | DI(AMINOGUANIDIUM) 4,4',5,5'-TETRANITRO-2,2'-BIIMIDAZOLE, AND PREPARATION METHOD THEREOF - According to the present invention, unstable hydrogen of 4,4′,5,5′-tetranitro-2,2′-biimidazole, which is a promising material for insensitive high-performance molecular explosives, may be stabilized by aminoguanidium to provide di(aminoguanidium) 4,4′,5,5′-tetranitro-2,2′-biimidazole, thereby solving the hygroscopicity of 4,4′,5,5′-tetranitro-2,2′-biimidazole, and enhancing performance and insensitivity thereof. | 08-09-2012 |
| 548313700 | Ring nitrogens of two diazole rings attached directly to the same atom or chain, which chain may include a ring, by nonionic bonding | 6 |
| 20090062551 | ELASTIC MATERIALS - The present invention relates to materials exhibiting the property of rubbery elasticity, consisting of molecules with a mass of between 9 and 9000 g/mol, all or some of the molecules having at least three groups (also referred to as “associative groups”) capable of associating via non-covalent interactions. | 03-05-2009 |
| 20090088575 | Process For Producing N,N'-Carbonyldiimidazole - The present invention provides a process for producing N,N′-carbonyldiimidazole, comprising: reacting phosgene, diphosgene, or triphosgene with imidazole in an inert solvent to produce N,N′-carbonyldiimidazole; to imidazole hydrochloride yielded as a by-product in the above step, adding a gaseous or liquid basic compound represented by the below-shown general formula (1) in an inert solvent to conduct neutralization reaction; and circulating the imidazole thus generated to use it as a starting material for N,N′-carbonyldiimidazole production. | 04-02-2009 |
| 20130204010 | Ionic Viscoelastics and Viscoelastic Salts - One embodiment of the present invention relates to ionic liquids and ionic viscoelastics formed between [1] a small molecule or macromolecule containing two or more cations; and [2] a small molecule or macromolecule containing two or more anions. Another embodiment of the invention is the use of the inventive ionic liquids and ionic viscoelastics, formed between a small molecule or macromolecule containing two or more cations and a small molecule or macromolecule containing two or more anions, to form a crosslinked network. In certain embodiments, the ionic liquids formed can be viscous liquids, viscous liquid formed networks, or viscoelastic networks/gels. In certain embodiments, the ionic material of the invention may be used for a variety of applications including, but not limited to, lubricants, additives, gas separation, liquid separation, membranes, fuel cells, sensors, batteries, coatings, heat storage, liquid crystals, biocompatible fluids, solvents, and electronic materials. | 08-08-2013 |
| 20130303783 | DEVICE AND PROCESS FOR CONTINUOUS PHOSGENATION - A continuous process for generation of phosgene from CO and Cl | 11-14-2013 |
| 20140179931 | Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas - The invention relates to a process for the synthesis of N-substituted cyclic alkylene ureas by reacting a multifunctional aliphatic amine A having at least two amino groups which may be primary or secondary, at least one of which is a primary amino group, —NH | 06-26-2014 |
| 20160009656 | SUPRAMOLECULAR MATERIALS MADE OF OLIGOAMIDES | 01-14-2016 |
| 548314700 | The additional hetero ring contains nitrogen as the only ring hetero atom [e.g., N-(cyclopentylcarbonyl-L-histidyl)-pyrrolidine, etc.] | 2 |
| 20100121074 | CYCLIC GUANIDINE IONIC LIQUID - Disclosed is an ionic liquid which is stable over a wide potential range and exhibits a high ionic conductivity. The ionic liquid comprises a cyclic guanidine salt represented by the following formula (1): | 05-13-2010 |
| 20150328341 | RADIOPHARMACEUTICAL PRODUCTS FOR DIAGNOSIS AND THERAPY OF ADRENAL CARCINOMA - A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic imaging method, e.g. for diagnosis of adrenocortical carcinoma. The compounds of formula (I) are further suitable for use in the treatment of adrenocortical carcinoma, by means of radionuclide therapy. | 11-19-2015 |
| 548315100 | The additional hetero ring contains sulfur as the only ring hetero atom [e.g., 5-(2-thienyl) hydantoin, etc.] | 5 |
| 20100137613 | PROCESS FOR EPROSARTAN - The present invention provides an improved and commercially viable process for preparation of eprosartan and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. Thus, for example, methyl 4-[[2-butyl-5-formyl-1 H-imidazol-1-yl]methyl]benzoate is reacted with ethyl 2-carboxy-3-(2-thienyl)propionate in the presence of a base, such as piperidine or piperidinium propionate in propionic acid, in cyclohexane solvent to give ethyl (αE)-α-[(2-n-butyl-1-[(4-(methoxy-carbonyl) phenyl]methyl]-1 H-imidazol-5-yl]methylene-2-thiophene propionate substantially free of decarboxylate impurity namely, ethyl 3-(2-thienyl)propionate, which is then subjected to base hydrolysis followed by treatment with methanesulfonic acid to obtain eprosartan mesylate in high purity and in high yield. | 06-03-2010 |
| 20110046391 | PROCESS FOR PREPARING EPROSARTAN MESYLATE - The present invention discloses a process for preparing eprosartan mesylate, in which eprosartan is dissolved or suspended in glacial acetic acid, then methanesulfonic acid is added and a solution of eprosartan mesylate in glacial acetic acid is obtained by stirring, a solid of eprosartan mesylate is precipitated by continuously stirring and then obtained by filtration, or a solid of eprosartan mesylate is obtained by concentrating the glacial acetic acid to dry, or a solid of eprosartan mesylate is obtained by adding dropwise an organic ester solvent into the glacial acetic acid under stirring to precipitate a crystal and separate the crystal. | 02-24-2011 |
| 20110054186 | PROCESS FOR EPROSARTAN INTERMEDIATE - The present invention provides an improved process for preparation of (E)-α-[[2-butyl-1-[[4-(methoxycarbonyl)phenyl]methyl]-1H-imidazole-5-yl]methylene]-2-thiophene propanoic acid ethyl ester in high purity and in high yield. Thus, for example, 4-[[2-butyl-5-formyl-1H-imidazole-1-yl]methyl]benzoic acid methyl ester is reacted with ethyl 2-carboxy-3-(2-thienyl)propionate in the presence of piperidinium propionate in diisopropyl ether or a mixture of n-hexane and a solvent selected from toluene and cyclohexane, optionally purifying the crude compound to obtain (E)-α-[[2-butyl-1-[[4-(methoxy carbonyl)phenyl]methyl]-1H-imidazole-5-yl]methylene]-2-thiophene propanoic acid ethyl ester substantially free of 3-(2-thienyl)propanoic acid ethyl ester impurity. | 03-03-2011 |
| 20140187788 | PROCESSES FOR THE PREPARATION OF THIETANAMINE - The present invention provides processes for the preparation of compounds of formula (I) including processes comprising a. reacting a a compound comprising a thietane moiety in which the carbon atom at the 3 position of the thietane moiety is bonded to a nitrogen atom; wherein the nucleophile is selected the group consisting of: N | 07-03-2014 |
| 20150368233 | CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT - Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that I | 12-24-2015 |
